Gujarat Fluorochemicals Q4FY26: Chemical growth holds up as battery investments weigh on consolidated margins

Gujarat Fluorochemicals Limited closed Q4FY26 with a clear split between what is already scaling and what is still being built. Consolidated revenue from operations rose 12 percent year on year to Rs. 1,369 crore, helped by stronger performance in the core chemical portfolio. Consolidated EBITDA was broadly flat at Rs. 308 crore versus Rs. 306 crore last year, and EBITDA margin fell to 22 percent from 25 percent. Consolidated profit after tax came in at Rs. 112 crore versus Rs. 162 crore in Q4FY25.

At the segment level, the picture looks sturdier. The chemical segment reported revenue of Rs. 1,358 crore, up 11 percent year on year, and EBITDA of Rs. 353 crore, up 13 percent. Chemical segment EBITDA margin improved to 26 percent from 25 percent, reflecting a stronger mix and better operating leverage in parts of the portfolio. Chemical segment PAT was Rs. 169 crore compared with Rs. 161 crore a year ago.

The consolidated gap versus the chemical performance is explained by the early-stage battery materials business, which posted revenue of Rs. 11 crore in the quarter and an EBITDA loss of Rs. 45 crore. That drag on profitability is not a surprise given the phase of commissioning, qualification, and ramp-up the company is currently navigating.

Quarter numbers in context

Two additional items matter for interpreting quarter-on-quarter and year-on-year profitability. In Q4FY26, PAT was stated before an exceptional item related to implementation of the new labour code, amounting to Rs. 2 crore net of tax in the chemical segment and Rs. 3 crore net of tax in consolidated results. Q4FY25 PAT, meanwhile, included Rs. 29 crore related to utilisation of brought forward capital losses where deferred tax asset was not recognised, and lower tax rate in respect of operating gains on slump-sale. These items do not change the direction of the quarter, but they do affect comparability.

On a sequential basis, the business accelerated. Consolidated revenue grew 21 percent quarter on quarter to Rs. 1,369 crore from Rs. 1,136 crore in Q3FY26. Chemical segment EBITDA grew 25 percent quarter on quarter to Rs. 353 crore from Rs. 283 crore, with margin inching up to 26 percent from 25 percent. Consolidated EBITDA rose 12 percent sequentially to Rs. 308 crore from Rs. 275 crore, but margin still slipped to 22 percent from 24 percent due to the battery materials loss.

Where growth came from: fluoropolymers strength and a fluorochemicals rebound

Within chemicals, fluoropolymers did the heavy lifting. The fluoropolymers vertical reported Q4FY26 revenue of Rs. 848 crore, up 19 percent year on year and 14 percent quarter on quarter. Management commentary pointed to volume-led growth, supported by price increases across key products. Even against a challenging global environment, this combination suggests the business is gaining share in priority applications and maintaining pricing discipline.

The outlook narrative is consistent with where global demand is moving. The company expects fluoropolymer demand to stay strong, driven by semiconductors, EV and battery energy storage systems, and clean energy. It also expects higher-performance fluoropolymers such as PFA and FKM to outgrow the broader category, linked to semiconductor fabs, AI-driven data center expansion, and advanced automotive applications. Over the longer term, management sees energy transition demand drivers such as hydrogen, fuel cells, electrolyzers, and solar.

Fluorochemicals were stable year on year but surged sequentially. Q4FY26 revenue was Rs. 319 crore, down 2 percent year on year from Rs. 326 crore, but up 63 percent quarter on quarter from Rs. 195 crore. The quarter included an important operational milestone: R32 production and sales commenced from March 2026. Management noted weakness in the Middle East market as a headwind, but also highlighted a favourable HFC pricing environment supported by disciplined global supply dynamics and healthy demand.

That combination matters. Refrigerant markets can be cyclical, and volumes and pricing often move with regulation and capacity discipline. The company is focused on optimizing HFC production and incremental capacity expansion to use its entitlements under the Kigali Amendment. Demand expectations remain healthy, supported by residential air-conditioning penetration, commercial refrigeration, cold-chain infrastructure, and the surge in cooling infrastructure demand from AI and data centers.

Bulk chemicals were steady and acted as a stabiliser rather than a growth engine. Q4FY26 revenue was Rs. 163 crore, up 1 percent year on year and down 3 percent quarter on quarter. Management expects caustic soda demand to remain stable in FY27 and pricing to be range-bound due to domestic capacity additions. Chloromethanes are also expected to remain range-bound.

Battery materials: commissioning is done, scale-up is next

The battery materials vertical is the strategic centerpiece of the next investment cycle, and Q4FY26 numbers show the cost of building ahead of revenue. The business posted Q4FY26 revenue of Rs. 11 crore, EBITDA of minus Rs. 45 crore, and PAT of minus Rs. 57 crore.

Management’s update is more about execution milestones than financial contribution, which is expected at this stage. It stated that all initial capacity planned in Phase I has been commissioned and contracted for, with anchor clients in place across products. Prices have firmed up for all battery materials over the last two quarters, which should help as volumes ramp.

The company’s demand thesis leans on a rapid expansion of ex-China lithium-ion battery demand. It expects ex-China LiB cell demand to grow from 500 GWh in CY26 to 1.8 TWh by CY30. It also links demand growth to BESS, driven by increased AI usage and corresponding data center demand.

On product progress, three items stand out:

First, LiPF6 has been approved by all major global electrolyte players, and commercial sales are scaling as per plan, with orders in place for FY27 and beyond.

Second, for LFP cathode active material, samples from the plant have received initial customer approvals, and the company expects to start commercial sales in H2FY27.

Third, in PVDF binder, the qualification process is complete, with commercial business expected in the first half of FY27.

The next build-out is also defined. The company is setting up an NGAAM anode facility and states that with this addition, the battery materials platform will cover about 70 percent of the value of an LFP cell cost. It has outlined planned capex of Rs. 2,300 crore for FY27 across the battery materials portfolio, largely growth capex including NGAAM. Overall capex remains at Rs. 6,000 crore by FY28, targeted at 2 times asset turnover and 25 percent plus EBITDA margin, with the full potential expected to be realized in FY29.

Funding visibility appears robust based on what has been tied up so far. Total funds raised or tied up were stated at about Rs. 3,730 crore, including Rs. 1,000 crore from Indian investors, Rs. 430 crore from IFC, and about Rs. 1,200 crore from Middle Eastern sovereign funds including OIA. In addition, about Rs. 1,100 crore has been infused or committed by the parent into the business.

The longer trend: improving profitability, but capital is rising

Beyond the quarter, FY26 shows steady scaling of the core business. Operating revenues rose to Rs. 4,996 crore in FY26 from Rs. 4,737 crore in FY25 and Rs. 4,281 crore in FY24. Exports remain the larger contributor, with FY26 export revenue of Rs. 3,017 crore versus domestic revenue of Rs. 1,979 crore.

Profitability has improved over the three-year view. EBITDA increased to Rs. 1,291 crore in FY26 from Rs. 1,157 crore in FY25 and Rs. 955 crore in FY24. EBITDA margin rose to 26 percent in FY26 from 24 percent in FY25 and 22 percent in FY24. PAT increased to Rs. 590 crore in FY26 from Rs. 517 crore in FY25 and Rs. 435 crore in FY24, and PAT margin improved to 12 percent.

Returns and working capital show the cost of expansion and mix shift. ROCE was 14.05 percent in FY26 versus 15.79 percent in FY25 and 14.63 percent in FY24. ROE was 12.17 percent in FY26 versus 14.80 percent in FY25 and 12.50 percent in FY24. Working capital days increased to 192 in FY26 from 188 in FY25 and 167 in FY24, with a note that FY26 includes four days of the GFCL EV business.

Capex guidance underscores a step-up. FY27 planned capex was shown as Rs. 800 crore for GFL and Rs. 2,300 crore for EV, compared with FY26 capex of Rs. 270 crore for GFL and Rs. 787 crore for EV. This creates a near-term tradeoff: higher depreciation and operating costs before revenues catch up, in return for building an integrated battery materials platform.

What investors can take away

Q4FY26 reinforces that Gujarat Fluorochemicals is running two arcs at once.

The first arc is the core chemical segment, where fluoropolymers continue to grow strongly, fluorochemicals showed a meaningful sequential rebound helped by the start of R32 sales, and bulk chemicals provide stable cash generation. Chemical segment margins improved, which suggests the core portfolio is still capable of compounding earnings even in a mixed global environment.

The second arc is battery materials, where the quarter’s losses are the visible cost of commissioning, qualification, and pre-scale operations. Management has provided a clear roadmap: Phase I capacities commissioned and contracted, approvals progressing across LiPF6, LFP CAM, and PVDF binder, and a defined capex and funding plan through FY28 with full potential expected in FY29.

The near-term headline is margin pressure at the consolidated level. The underlying story is disciplined execution in the legacy business and a structured build-out of a new platform aimed at EV and ESS supply chains. If approvals translate into stable offtake and the capex program delivers the targeted asset turnover and margin profile, FY27 and FY28 should be viewed as transition years that set up the next phase of earnings mix.